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Abstract: BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy
(ALPPS) is a novel strategy to resect liver tumors despite the small size of the liver remnant. It is an
hepatectomy in two stages, with PVL and parenchymal transection during the first stage, which induces
rapid growth of the remnant liver exceeding any other technique. Despite high postoperative morbidity
and mortality in most reports, the technique was adopted by a number of surgeons. MATERIALS AND
METHODS: This systematic review explores current data regarding the feasibility, safety, and oncologic
efficacy of ALPPS; the search strategy has been published online. A meta-analysis of hypertrophy, feasi-
bility (ALPPS stage 2 performed), mortality, complications, and R0 (complete) resection was performed.
RESULTS: A literature search revealed a total of 13 publications that met the search criteria, reporting
data from 295 patients. Evidence levels were low, with the highest Oxford evidence level being 2c. The
most common indication was colorectal liver metastasis in 203 patients. Hypertrophy in the meta-analysis
was 84 %, feasibility (ALPPS stage 2 performed) 97 % (CI 94-99 %), 90-day mortality 11 % (CI 8-16
%), and complications grade IIIa or higher occured in 44 % (CI 38-50 %) of patients. A standardized
reporting format for complications is lacking despite the widespread use of the Clavien-Dindo classifi-
cation. Oncological outcome is not well-documented. The most common topics in the selected studies
published were technical feasibility and indications for the procedures. Publication bias due to case-series
and single-center reports is common. CONCLUSION: A systematic exploration of this novel operation
with a rigid methodology, such as registry analyses and a randomized controlled trial, is highly advised.
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ABSTRACT
Background. Associating liver partition and portal vein
ligation for staged hepatectomy (ALPPS) is a novel strat-
egy to resect liver tumors despite the small size of the liver
remnant. It is an hepatectomy in two stages, with PVL and
parenchymal transection during the first stage, which
induces rapid growth of the remnant liver exceeding any
other technique. Despite high postoperative morbidity and
mortality in most reports, the technique was adopted by a
number of surgeons.
Materials and Methods. This systematic review explores
current data regarding the feasibility, safety, and oncologic
efficacy of ALPPS; the search strategy has been published
online. A meta-analysis of hypertrophy, feasibility (ALPPS
stage 2 performed), mortality, complications, and R0
(complete) resection was performed.
Results. A literature search revealed a total of 13 publi-
cations that met the search criteria, reporting data from 295
patients. Evidence levels were low, with the highest Oxford
evidence level being 2c. The most common indication was
colorectal liver metastasis in 203 patients. Hypertrophy in
the meta-analysis was 84 %, feasibility (ALPPS stage 2
performed) 97 % (CI 94–99 %), 90-day mortality 11 % (CI
8–16 %), and complications grade IIIa or higher occured in
44 % (CI 38–50 %) of patients. A standardized reporting
format for complications is lacking despite the widespread
use of the Clavien–Dindo classification. Oncological out-
come is not well-documented. The most common topics in
the selected studies published were technical feasibility and
indications for the procedures. Publication bias due to case-
series and single-center reports is common.
Conclusion. A systematic exploration of this novel oper-
ation with a rigid methodology, such as registry analyses
and a randomized controlled trial, is highly advised.
Associating liver partition and portal vein ligation for
staged hepatectomy (ALPPS) was first coined as an epo-
nym for a new technique in liver surgery to perform
trisectionectomies with marginal remnant liver volume in a
two-stage surgical procedure by inducing hypertrophy of
the left liver by right portal vein ligation (PVL) and
parenchymal transection,1 referred to as ‘in situ splitting’ in
the original publication.2 The technique induced more
hypertrophy of the remnant liver in less time than portal
vein embolization (PVE)3 and PVL.4 Even when compared
with recent reports of highly selective portal branch
embolization with microspheres promising hypertrophy of
the future liver remnant (FLR) of more than 60 %5 over
several weeks, in ALPPS the liver remnant increases at an
approximately tenfold increased growth rate in only 1 or
2 weeks.6 The technique was adopted by a number of liver
surgeons, but also led to debate due to a relevant morbidity
and perioperative mortality.5,7–9 This systematic review
was performed to assess the published evidence for feasi-
bility, safety, and oncological efficacy of ALPPS. We also
discuss how far the consensus recommendations on surgi-
cal innovations, as developed by the Balliol group (the so-
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called Innovation Development Exploration Assessment
and Long-term study [IDEAL] recommendations10), cap-
ture what happened when ALPPS was introduced in the
surgical literature.
MATERIALS AND METHODS
Review Protocol and Registration
A systematic review protocol was developed and made
available online (www.alpps.net) and on the international
PROSPERO database (CRD42014009159).
Information Sources
A search of the databases Pubmed, Cochrane, EM-
BASE, and SCOPUS was performed. There were no
language restrictions. Reference lists of relevant articles
were reviewed and duplicates were removed. Studies
unrelated to ALPPS, as well as abstracts, were excluded.
Full-text articles were assessed for eligibility. All letters,
editorials, and opinion articles, as well as case reports,
were excluded. Studies reporting on up to three patients
were classified as case reports. Manuscripts were tabulated
in a qualitative synthesis and categorized into levels of
evidence in accordance with the definition of the Centre of
Evidence in Medicine in Oxford (http://www.cebm.net/
index.aspx?o=1025). Patients were carefully screened for
double reporting of patients and, after exclusion of those
patients, a quantitative synthesis/meta-analysis was
performed.
Study Selection and Data Collection Process
Figure 1 shows the study selection and data collection
process. Data collection forms were used to extract data
items from each included study.
Duplicates removed
Databases and numer of records identified:
Medline 122, Embase 254, Cochrane 1, Scopus 164. Total 541 records
Last search performed on Mai 12th 2014



























Qualitative synthesis Table 1 to 3
(Studies n = 13)
(Patients n = 397)
Quantitative synthesis Fig. 2A -E
(Studies n = 6)




FIG. 1 Prisma flowchart of databases searched, strategy used, and exclusions performed. ALPPS Associating Liver Partition and Portal vein
ligation for Staged hepatectomy
3110 E. Schadde et al.
Data Items and Summary Measures
Information on baseline descriptors of the patient pop-
ulations undergoing ALPPS was extracted from the studies
selected for analysis; age, tumor type, surgical approach
(laparoscopic vs. open), preoperative chemotherapy, pre-
operative volumetry, and the time between stages and
kinetic growth (in cc/day) were examined in each study.
We also evaluated the indication to perform ALPPS as
reported in the studies; ALPPS has either been reported in
the context of liver tumors with FLRs too small for one-
stage surgery (‘marginally resectable’) or as a salvage
strategy after previous portal vein manipulation of some
kind that did not result in adequate growth to proceed with
the resection (‘salvage’), such as f.e. PVE.
Data collection on outcomes was divided into three
questions:
(1) How feasible is ALPPS? The first feasibility end-
point is hypertrophy of the liver remnant between stages.
Centers were contacted to report their data as means with
standard deviation rather than as a median, as is customary
when undertaking a meta-analysis. As a second feasibility
endpoint, the percentage of patients who achieved tumor
removal in a stage 2 operation was chosen. The purpose of
ALPPS is to remove the entire tumor load of a liver with
extensive tumor burden within a short period of time. It is
known that two-stage hepatectomies result in incomplete
removal of tumor whenever stage 2 cannot be performed.
We therefore defined feasibilty of resection as performance
of stage 2 with macroscopic removal of tumor.
(2) How safe is ALPPS? The main safety endpoint was
90-day or in-hospital mortality. We choose both since 90-
day mortality is not consistently reported. Overall com-
plication rate and rate of complications grade IIIa and IIIb
or higher were examined. Bias of the individual studies was
categorized based on study design. The main discussion
points and the virtues of each study were independently
extracted by two authors (ES and AAS). Mortality and
complications grade IIIa or higher were summarized in a
meta-analysis.
(3) How effective is ALPPS in treating colorectal liver
metastases (CRLM) oncologically? Data on complete (R0)
versus incomplete resection (R1), overall survival (OS),
and disease-free survival (DFS) were examined. Summary
measures were only performed for completeness of resec-
tion due to the paucity of data for OS and DFS.
Statistics
Data are presented in parametric or non-parametric
fashion depending on their presentation in the original
publications. The software Comprehensive Meta-Analysis
(Biostat, Englewood, NJ, USA) was used to generate the




A literature search revealed a total of 51 full-text publi-
cations (Fig. 1). Twenty-one studies were excluded because
they represented editorials, letters, and opinion pieces, and
17 contained case reports, which were also excluded. Thir-
teen studies were tabulated in a qualitative synthesis (see
Tables 1, 2, and 3), with a total of 397 patients. Six studies
could be evaluated in a quantitative synthesis after exclusion
of seven publications reporting patients who were later
included in larger reports. Of these, a quantitative meta-
analysis could be performed on two to six studies, depending
on available data.
Classification into Evidence-Level Groups
Of 13 studies, 10 were case-series, which were consid-
ered evidence level 4 (Table 1). Two comparative studies
have been published which include a total of 55 patients
undergoing ALPPS. One study compares 7 patients with
ALPPS with 15 patients with PVE,12 and is classified as
evidence level 4 due to the small number of patients. The
second study compares 48 patients with ALPPS with 86
patients undergoing PVE or PVL.6 It constitutes evidence
level 3b as it is an individual cohort study with a multi-
variate analysis to adjust for confounders. Analysis of the
ALPPS registry, including 202 patients,13 was classified as
‘outcomes research’ or evidence level 2c.
Characteristics of Patients and Feasibility of ALPPS
The most frequent indications for ALPPS were CRLM
in 199 patients, followed by hepatocellular cancer (HCC)
in 22 patients, perihilar cholangiocarcinoma (PHCC) in 21
patients, intrahepatic cholangiocarcinoma (IHCC) in 14
patients, gallbladder cancer (GBCA) in 7 patients, and non-
CRLM (NCRLM) in 25 patients (Table 1). Indications
were not reported for seven patients.12 In all studies, AL-
PPS was used for initially non-resectable liver tumors; a
salvage approach is additionally described in five studies.
Overall, there were seven patients in whom laparoscopic
ALPPS was reported.
The increase of liver volume can only be summarized in
an analysis of two studies2,13 because other groups did not
report their mean increase of volume with standard devi-
ations, even after individual requests. The summary






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3112 E. Schadde et al.
increase of only two studies was 84 %, with a confidence
interval (CI) of 78–91 % (Fig. 2a).
The majority of studies reported a waiting interval
between stages of approximately 1 week. FLR proportion
to total liver volume or standardized FLR (sFLR) prior to
stage 1 is around 0.20, and around 0.40 prior to stage 2. A
meta-analysis was not performed for the size of the FLR
because all studies reported medians. sFLR, as calculated
according to a well-established methodology in liver sur-
gery,14 is used by only 3 of 13 reports.
Completion of ALPPS in stage 2 may be summarized in
an analysis of six studies. Four of these studies reported
100 % progression to stage 2, but in the meta-analysis their
results have to be weighted accordingly.In the meta-ana-
lysis their feasibility therefore does not equal 100 %. In
summary, the feasibility rate (percentage of stage 2 per-
formed) was 97 % (CI 94–99 %) [Fig. 2b]. Data on
outcomes patients not undergoing stage 2 were only
available from the registry analysis for 4 patients over-
all. Two patients had CRLM—one patient died
perioperatively after stage 1, and one patient died from
tumor progression 6 months after stage 1. A third patient
with primary angiosarcoma of the liver could not undergo
stage 2 and died from tumor progression after 6 months,
while a fourth patient with PHCC died from tumor pro-
gression after 3 months.
Safety of ALPPS
A summary of the primary safety endpoint 90-day
mortality or in-hospital mortality is presented in Table 2
and Fig. 2c. The meta-analysis shows an 11 % mortality
rate with a CI of 8–16 %.
The majority of studies, but not all, used a standardized
reporting format for complications, such as the Clavien–
Dindo classification. It is therefore difficult to clearly
delineate complications reported in all studies. In the meta-
analysis, 44 % of patients experienced complications grade
IIIa or higher, with a confidence interval of 38–50 %
(Fig. 2d).
Risk of Individual Study Bias
In the 13 selected studies, the most common bias found
was related to single-center case-series (nine studies), ret-
rospective analyses (two studies), followed by the reporting
bias of a voluntary registry (one study), and lack of a
control group (11 studies) (Table 2).
Study Topics
The most common topics in the selected studies pub-


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3116 E. Schadde et al.
induce rapid hypertrophy with ALPPS (five studies), fol-
lowed by discussion of safety (two studies) and indications
(two studies). In two studies, the main aim was to compare
ALPPS with conventional methods to manipulate the portal
vein (Table 2).6,12 Several studies reported the difficulty to
analyze survival when mixed indications are reported,2,6
while only one study explicitly focused on oncological
outcome.15
Oncologic Efficacy of ALPPS
Completeness of resection (R0) was achieved in 91 % of
patients, with a CI of 87–94 % (Table 3 and Fig. 2e). OS
and DFS were rarely reported adequately, with the
exception of two studies,13,16 and were therefore not
evaluated in a meta-analysis. Some studies reported
unconventional time points, such as 62 or 11 months15 to
evaluate survival, and numbers were too small to evaluate
survival separately for different tumor etiologies. Despite
this lack of data, 10 of 13 studies hypothesized on onco-
logical issues in the discussion section of their reports.
DISCUSSION
This analysis shows that 2 years after the inaugural
publication of the novel ALPPS technique of two-stage
hepatectomy, the level of evidence supporting its use
remains low (no study higher than 2c). Studies confirm the
feasibility of 97 % for completion of both stages of resec-
tion, with the two most common biases of single-center and
retrospective design. Perioperative mortality was 11 %,
with a CI of 8–16 %, and complications grade IIIa or higher
occured in 44 %, with a CI of 38–50 %. The main discus-
sion point in the literature wae technical feasibility of the
procedure. Only two studies systemically addressed median
follow-up, median survival and median DFS.
This systemic review was limited due to the small
number of original publications in a very recently-intro-
duced technique. The reason for an early systematic review
is to support, with data, the ongoing debate on the benefits
of ALPPS in surgical oncology of the liver. Warnings about
performing a randomized trial have been brought forward
due to the lack of safety of ALPPS.9 At the same time, the
quality of studies published does currently not allow the
establishment of solid evidence of safety and efficacy, as
shown by this review. Centers performing ALPPS who are
interested in publishing their individual experience should
be encouraged to address standard data items in their pub-
lications which allow for an assessment of feasibility,
safety, and oncologic efficacy, or, alternatively, enter their
data into an easily accessible international database (www.
alpps.net).
The tendency of surgical innovators to provide reports
based on experience rather than systematically test a new
procedure should be discussed in the context of the Balliol
recommendations on surgical innovation. McCulloch et al.
developed a paradigm for surgical innovation, and classi-
fied five stages of surgical innovation: (1) innovation; (2)
development; (3) systematic exploration; (4) assessment;
and (5) long-term study (abbreviated with the eponym
‘‘IDEAL’’).10 The discovery of ALPPS was a surgical
innovation and the paradigm ought to be applicable. While
comparing the reality of surgical innovation in ALPPS with
the IDEAL recommendations, we made four observations.
First, according to McCulloch et al., during the inno-
vation stage (1) dramatic successes or failures were
reported in single-digit case reports from individual cen-
ters. However, in the case of ALPPS, the inaugural
publication was a multicenter report with a double-digit
number of patients reported and detailed reporting of
indications and complications. The inaugural study belongs
to the ‘development stage’ (stage 2a) rather than the
‘innovation stage’ (stage 1), according to the Balliol par-
adigm. Interestingly, this inaugural report was followed by
a wave of case reports and single-center-experience reports
that characterize the ‘innovation stage’ (stage 1) in the
Balliol paradigm. These studies do not contribute evidence
beyond the level of the inaugural study, neither in the
number of patients presented nor in systematic reporting of
outcome data. Maybe due to the publication pressure in
academic centers, individual center reports dominate over
collaborative work in this field of surgical oncology. Let-
ters are common and there is a wide divergence of opinion
between supporters and critics without new data. Expert
centers reported problems associated with ALPPS but their
reports remain narrative.7
Second, according to the IDEAL paradigm, studies
following the ‘innovation stage’ belong to the ‘develop-
ment stage’, practiced by ‘early adaptors’. At this stage,
‘‘few patients are being recruited, they are selected for
specific characteristics’’.17 In reality, ALPPS was per-
formed for a wide range of indications and may have been
overused as a magic bullet in high-risk patients with rap-
idly progressive malignancies. This ‘expanded’
development phase has made ALPPS known for its high
risk of complications, and mortality has led to warnings by
some about an ‘immature procedure’.9 This recoil may
explain a temporary contraction in the number of proce-
dures recorded in the ALPPS registry in 2013 (Schadde E,
personal communication) and a general pessimism, which
may be unjustified if a more homogeneous patient popu-
lation is chosen.
The third observation is a hesitancy to enter the
‘exploration phase’ (stage 2b) after the development phase
postulated by the IDEAL paradigm. In the exploration
Systematic Review and Meta-Analysis of ALPPS 3117
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phase, a larger patient population with clearly defined
indications is treated by an early majority of surgeons.
Recently, it has been argued that a randomized controlled
trial (RCT) should not be performed until the safety of
ALPPS has been established in a ‘phase I process’.9 This
concern is understandable since, as this review shows, the
majority of studies available today belong to the ‘innova-
tion phase’ and present incomplete data, with the
‘development phase’ somewhat omitted. However, despite
this concern, the IDEAL recommendations state that RCTs
should be initiated before the plateau of the learning curve
has been reached, since the rigid supervision of outcomes
in a randomized multicenter trial is superior to individual
practice in single centers. According to the Balliol state-
ment, procedures not sufficiently evolved to warrant full
evaluation may evolve further during the trial.10 Addi-
tionally, there are now safety data available in the form of a
registry.13 Registries are recommended by the Balliol
cooperation—additionally to RCTs–during the exploration
phase. The recently performed registry analysis13 can
therefore be considered to be a first step in the ‘exploration
phase’. According to the Balliol statement, during the
exploration stage enough reports have been published for
the technology to be generally regarded as safe, and it is
starting to lose its experimental character, although it is
still novel.17 Our meta-analysis shows a CI for mortality in
mixed indications of 8–16 %. Mortality of ALPPS for
CRLM is 8 % in the registry analysis and 5.1 % in patients
with CRLM younger than 60 years of age.13 This subset of
patients was explored because a high mortality was
observed for primary liver tumor indications in older
patients. While conventional two-stage hepatectomy have
primarily been performed in younger patients with CRLM
(for example median age of 53 years (range 35–69) in the
largest study18), ALPPS has been used by many as a magic
bullet for older patients with primary liver cancers due to
the allure of the ‘auxiliary livery’ left in place. Recently, a
systematic review of the mortality of conventional two-
stage hepatectomy for CRLM has been performed, with a
range of 0–8 % and a mean of 3 %. As the authors admit,
3 % was not generated using weighing by meta-analysis.
Studies included were a large series from Paul-Brousse
Hospital, Paris, with a mortality of 7 %,19 a large series
from MD Anderson Cancer Center, with a perioperative
mortality of 6 %,18 and the series from John-Hopkins
Hospital, with a perioperative mortality of 6 %.20 There-
fore, it appears that mortality of ALPPS is comparable to
that of conventional two-stage hepatectomies, as long as
comparable populations are actually compared. ALPPS for
a population with strict inclusion criteria (CRLM, younger
than 60 years of age) appears safe enough to be consider a
randomized trial. One could also argue that only a ran-
domized trial with strict inclusion criteria, under the strict
surveillance of a Data Safety Monitoring Board ready to
recommend that the trial be stopped if a too-high mortality
rate occurs, may settle the controversy regarding the
mortality of ALPPS.
Since the feasibility of two-stage hepatectomy to reach
complete tumor resections is only 77 %,21 and the feasi-
bility of ALPPS is 97 %, an RCT with an oncological
endpoint, such as for example 1-year DFS, should be
seriously considered. The largest report with complete
survival data of TSH in patients with CLRM shows a DFS
of 39 % at 1 year.18 Two other reports detail a median
survival of 12 months or more but they are smaller and
their populations differ from the population analyzed in the
ALPPS registry analysis. If a difference of proportions of
20 % in DFS is assumed, together of a power of 0.8,
approximately 110 (accounting for dropouts) subjects
would have to be enrolled in each arm. The equipoise of
ALPPS and conventional two-stage hepatectomies consists
of the simple fact that ALPPS has a feasibility of 97 %
with a CI of 93–98 %, as shown by this review. Conse-
quently, two RCTs investigating ALPPS versus
conventional two-stage hepatectomies were recently laun-
ched (clinicaltrials.gov-identifier: NCT01775267 and
NCT01842971).
CONCLUSIONS
ALPPS appears to have a high feasibility of resecting
primarily non-resectable liver tumors, and a mortality
comparable to conventional two-stage hepatectomies. Data
on oncologic outcomes are missing and have not been
systematically reported by individual studies. The tech-
nique should not only be explored by further accrual of
patients and analysis of registry data but also in an RCT of
ALPPS versus two-stage hepatectomy for CRLM.
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